Diarrhea News and Research

Latest Diarrhea News and Research

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

AMAG Pharmaceuticals, Inc. today provided an update on the commercial launch of Feraheme® (ferumoxytol) Injection for intravenous (IV) use, including preliminary fourth quarter 2009 Feraheme net product revenues estimates, as well as an update on the Company’s international and label expansion efforts.

10 Jan 2010

Recent releases in Global Health

A Lancet Comment examines the "grossly insufficient" progress towards meeting the Millennium Development Goal (MDG) of reducing under-5 child mortality. "Accelerated progress can be achieved, even in the poorest environments, through: integrated, evidence-driven, and community-based programmes that focus on addressing the major causes of death, including pneumonia, diarrhoea, newborn disorders, malaria, HIV, and undernutrition; reaching the unreached with a basic package of interventions at large scale and achieving coverage with equity; and using data for action and advocacy," the comment concludes (You et al., 1/9).

9 Jan 2010

3Sbio submits registrational clinical trial application for Feraheme injection

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a registrational clinical trial to the Chinese State Food and Drug Administration ("SFDA") for Feraheme (ferumoxytol) Injection for intravenous use.

8 Jan 2010

CCAC doubles its efforts to convince Canadians to prevent colorectal cancer

Following the results of the Angus Reid Strategies and the Applied Health Research Centre at Toronto's St. Michael's Hospital survey conducted on behalf of the Canadian Partnership Against Cancer finding that the majority of Canadians have a good understanding of the benefits of colorectal cancer screening, but are not taking action to get screened, the Colorectal Cancer Association of Canada ("CCAC") is doubling its efforts in 2010 to convince Canadians that they must be more proactive concerning their health and the onset of colorectal cancer.

7 Jan 2010

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose “Quad” regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.

7 Jan 2010

Texas Mutual Insurance offers tips to prevent H1N1 flu

Flu season peaks in January and February. For adults, the workplace is the most common place to catch the flu.

7 Jan 2010

Also in global health news: ART access in Zimbabwe; Indonesia bird flu deaths; Kenya floods; Solomon Island tsunami

Zimbabwe's government plans work with international organizations to increase the number of people receiving anti-retroviral therapy (ART) to 300,000 by the end of the year, up from the 180,000 who currently get the drugs, Henry Madzorera, the country's health minister, said on Tuesday, ZimOnline reports.

6 Jan 2010

Opinions: U.S. medical emergency response; micronutrients; rotavirus vaccine; antibiotic development

"[D]espite the tireless efforts of public health and health-care workers, America's experience with H1N1 shows that the nation is not prepared to deal with a flu pandemic," former Democratic Senator Bob Graham and former Republican Senator Jim Talent write in Washington Post opinion piece that examines U.S. preparedness for medical emergencies. The writers chaired the Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism.

6 Jan 2010

Water experts plan coordinated approach towards global water crisis

More than two dozen leading United Nations water experts will convene in Hamilton, Canada Feb. 2-4 to plan fresh strategy for a coordinated approach to the global water crisis that increasingly threatens both human health and international security.

5 Jan 2010

St. John's wort not effective in treating IBS

A Mayo Clinic research study published in the January issue of the American Journal of Gastroenterology finds that St. John's wort is not an effective treatment for irritable bowel syndrome (IBS). While antidepressants are frequently used to treat IBS, to date, no study has examined the success of using the herbal supplement St. John's wort in treating IBS.

5 Jan 2010

VELCADE sNDA receives FDA approval

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

5 Jan 2010

University of Western Ontario receives grant to conduct randomized trial for Crohn's disease

Robarts Clinical Trials at The University of Western Ontario in London, Canada, has been awarded a 4.7 million dollar grant to conduct a randomized controlled trial evaluating treatment options for Crohn's disease.

5 Jan 2010

Parents and physicians should lookout for common GI symptoms in ASD patients, says landmark report

A causal relationship between gastrointestinal disorders and the behavioral features of children with autism spectrum disorder has been acknowledged for years by parents caring for those affected, yet dismissed by mainstream medicine.

4 Jan 2010

Health risks of wooden pallet shipping platforms, call for Congress and FDA regulation

The expanded recall of TYLENOL Arthritis pain reliever is fresh evidence of the need for Congress and the FDA to regulate wood pallets used to transport food and pharmaceuticals in the United States because of the dangers they pose to human health.

4 Jan 2010

Pfizer provides update on Prevnar 13

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the Biologics License Application (BLA) for Prevnar 13™, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s candidate 13-valent pneumococcal conjugate vaccine.

31 Dec 2009

Santarus submits rifamycin SV MMX IND to the FDA

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) requesting approval to begin a Phase III clinical program evaluating rifamycin SV MMX® in patients with travelers’ diarrhea.

30 Dec 2009

Fred Pritzker calls on meat suppliers to pay medical bills incurred by victims of E. coli

National food safety lawyer Fred Pritzker is calling on National Steak and Poultry company to immediately pay all medical bills and lost wages incurred by victims of a multi-state outbreak of E. coli O157:H7 associated with blade-tenderized steaks.

30 Dec 2009

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Eli Lilly and Company (NYSE: LLY), Kowa Company, Limited, and Kowa's U.S. subsidiary, Kowa Pharmaceuticals America, Inc., today announced that Lilly and Kowa Pharmaceuticals America have entered into a co-promotion agreement in the United States to commercialize LIVALO® (pitavastatin). Lilly and Kowa have also entered into a licensing agreement in Latin America. LIVALO is a statin approved by the U.S. Food and Drug Administration (FDA) in August 2009 for the treatment of primary hyperlipidemia and mixed dyslipidemia.

24 Dec 2009

Colcrys Patient Assistance Program introduced by URL Pharma

URL Pharma, Inc. announced the launch of the Colcrys® (colchicine, USP) Patient Assistance Program, an initiative that will allow patients with limited means to save on Colcrys prescriptions. This program reflects URL Pharma's ongoing commitment to helping ensure that all patients who rely on the company's medications are able to access them, regardless of economic status. Colcrys is indicated for the prevention and treatment of gout flares and for the treatment of Familial Mediterranean Fever (FMF).

24 Dec 2009

New compound may halt drug-resistant lung cancer

The ability to make, test, and map the atomic structure of new anti-cancer agents has enabled a team of Dana-Farber Cancer Institute scientists to discover a compound capable of halting a common type of drug-resistant lung cancer.

24 Dec 2009

Diarrhea News and Research

Latest Diarrhea News and Research

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

Recent releases in Global Health

3Sbio submits registrational clinical trial application for Feraheme injection

CCAC doubles its efforts to convince Canadians to prevent colorectal cancer

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Texas Mutual Insurance offers tips to prevent H1N1 flu

Also in global health news: ART access in Zimbabwe; Indonesia bird flu deaths; Kenya floods; Solomon Island tsunami

Opinions: U.S. medical emergency response; micronutrients; rotavirus vaccine; antibiotic development

Water experts plan coordinated approach towards global water crisis

St. John's wort not effective in treating IBS

VELCADE sNDA receives FDA approval

University of Western Ontario receives grant to conduct randomized trial for Crohn's disease

Parents and physicians should lookout for common GI symptoms in ASD patients, says landmark report

Health risks of wooden pallet shipping platforms, call for Congress and FDA regulation

Pfizer provides update on Prevnar 13

Santarus submits rifamycin SV MMX IND to the FDA

Fred Pritzker calls on meat suppliers to pay medical bills incurred by victims of E. coli

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Colcrys Patient Assistance Program introduced by URL Pharma

New compound may halt drug-resistant lung cancer

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Diarrhea News and Research

Latest Diarrhea News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in